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ABSTRACT
Purpose. Quality of care and its measurement represent a
considerable challenge for pediatric smaller-scale com-
prehensive cancer centers (pSSCC) providing surgical
oncology services. It remains unclear whether center size
and/or yearly case-flow numbers influence the quality of
care, and therefore impact outcomes for this population of
patients.
Patients and Methods. We performed a 14-year, retro-
spective, single-center analysis, assessing adherence to
treatment protocols and surgical adverse events as quality
indicators in abdominal and thoracic pediatric solid tumor
surgery.
Results. Forty-eight patients, enrolled in a research-asso-
ciated treatment protocol, underwent 51 cancer-oriented
surgical procedures. All the protocols contain precise
technical criteria, indications, and instructions for tumor
surgery. Overall, compliance with such items was very
high, with 997/1,035 items (95 %) meeting protocol
requirements. There was no surgical mortality. Twenty-one
patients (43 %) had one or more complications, for a total
of 34 complications (66 % of procedures). Overall, 85 %
of complications were grade 1 or 2 according to Clavien–
Dindo classification requiring observation or minor
medical treatment. Case-sample and outcome/effectiveness
data were comparable to published series. Overall, our data
suggest that even with the modest caseload of a pSSCC
within a Swiss tertiary academic hospital, compliance with
international standards can be very high, and the incidence
of adverse events can be kept minimal.
Conclusion. Open and objective data sharing, and dis-
cussion between pSSCCs, will ultimately benefit our
patient populations. Our study is an initial step towards the
enhancement of critical self-review and quality-of-care
measurements in this setting.
The objective measurement of quality of care is crucial
for the improvement of services provided to children with
cancer. In Switzerland, as in other European countries,
there is a reflection on centralization of highly specific
healthcare services, such as pediatric oncology. In this
setting, we found it essential to monitor the quality of the
services provided at a given time.
Unfortunately, obtaining reliable data on performance,
safety, and overall outcomes represents a major challenge
in pediatric surgical oncology, even more so in low-out-
put, but nonetheless reference/tertiary, hospitals. This
issue particularly affects pediatric smaller-scale compre-
hensive cancer centers (pSSCC). Globally, it remains
unclear which specific determinants, either in size or
related overall case turnover of the providing center,
directly or indirectly influence outcomes. Moreover,
comparisons between pediatric surgical oncology centers
remain particularly difficult due to (a) the rarity of the
diseases managed, all of which are classifiable as
orphan;1,2 and (b) the extreme diversity in the encountered
clinical spectrum.
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The dilemma is whether minimal requirements in case
numbers and/or mere center size criteria (i.e. in number of
certified dedicated physicians or nursing staff) should be
added to published guidelines.3 In fact, it is undoubtedly
essential not only for the patients, but also for the rational
use of medical and financial resources, that pSSCC meet
proper standards of care, and achieve results comparable to
larger centers.
As the economical impact of healthcare has become a
more vigorous modulator of political decisions, it is
imperative that smaller institutions address the question of
quality in pediatric surgical oncology, and provide evi-
dence to support or modify the existing lines of practice. In
fact, while larger institutions have the privilege of experi-
ence from the abundance of treated cases, it remains to be
proven that outstanding care can be provided at a smaller
scale.
Solid malignant tumors account for 35–40 % of all
pediatric malignancies, and make up to 50 % of cancer-
related deaths.4,5 Neuroblastoma, renal tumor, and other
abdominal or thoracic tumors account for 6, 5.2 %, and less
than 1 %, respectively, of pediatric cancers according to
the Swiss Childhood Cancer Registry.6 International
research-associated treatment protocols have helped reduce
these dim figures, as exemplified by improved survival and
lower morbidity in neuroblastoma after implementation of
the results of multicentric studies.7,8 Complementary to
other treatment modalities, surgical excision is often an
important step in the management of these tumors.
The extent to which eligible children are actually
included in research-associated treatment protocols is
usually not reported in the literature, and should be
regarded as an indicator of quality of care in pediatric
oncology patients, similar to compliance with published
guidelines in other fields of healthcare.9 Adverse event
rates are another important quality indicator. Cancer is a
systemic disease and pediatric surgical oncology is often
performed on children in physiological distress, therefore
more prone to complications. Yet again, little has been
published on this issue, which may be associated with
negative values in medical and surgical tradition, instead of
being an incentive for improvement. Notwithstanding the
existing controversy regarding the use and definitions of
‘complications’, ‘adverse events’, or ‘adverse occur-
rences’, these phrasings will be used interchangeably in
this work.10
In Switzerland, all pediatric oncology patients are
referred, without pre-selection, to one of the five pediatric
cancer centers such as ours which are equipped to manage
all complex cases. With this single-center, retrospective
study spanning 13 years of practice, we desired to critically
address the compliance of our unit to enrollment into
standard-of-care treatment protocols, and measure the rate
of adverse events observed in our patient population over
the last 13 years. The hypothesis was that these two indi-
cators could allow basic but reliable comparisons with
larger centers and serve as proxies for quality of care.
Survival data were also assessed for comparison purposes.
PATIENTS AND METHODS
The study protocol was approved by the Lausanne
University Research Ethics Committee for Human
Research (number 217/11, 10 June 2011). Written consent
was given by the patients for their information to be stored
in the hospital database and used for research.
Medical and surgical files of all children \18 years of
age who were operated on in our institution between 1
January 1997 and 31 December 2010 were searched both
electronically and manually for diagnosis of neuroblas-
toma, nephroblastoma, primary neuroectodermal tumor
(PNET) or other abdominal and thoracic primary solid
malignancies, as well as for surgical codes. Patients with a
differential diagnosis of malignant tumor who ended up
having a benign mass were included up to the point of
histological diagnosis of a non-malignant process. Simple
biopsies were not included. Patients with central nervous
system (CNS) tumors were excluded, as were patients
operated primarily for excision or staging in another
institution and referred secondarily. For more homogene-
ity, patients with germinal tumors were not included. All
patients were managed and/or supervised by one dedicated
pediatric oncology surgeon.
Patients’ records were then checked for inclusion in a
protocol, and for accordance to every single identifiable
surgical item of each effective protocol. The protocol
details are listed in Table 2.
Compliance with non-surgical directives was not
recorded or analyzed. Overall compliance was summarized
as the proportion of items satisfactorily verified to the total
number of items. Rates are expressed in percentages, and
ages are expressed as medians.
Early (i.e. within 30 days of surgery) and late compli-
cations, defined as deviations from the ideal postoperative
course, were identified with the help of diagnostic codes
and through manual searching, and graded according to
Clavien and Dindo.11
Primary endpoints were (1) inclusion into an interna-
tional protocol; (2) adherence to the effective protocol; (3)
surgical mortality; and (4) complication/adverse event
rates. Secondary endpoints were (1) completeness of sur-
gical tumor removal when indicated; (2) time to enteral
feeding; (3) possible delay of postoperative chemotherapy
when required; and (4) survival.
A 14-Year Retrospective Single-Center Analysis 1727
RESULTS
Sixty-one eligible patients were identified, of whom 50
underwent 53 cancer-oriented surgical procedures and were
included in the study population. Clinical and demographic
data are described in Table 1.
All operations were performed by, or under direct
supervision of, a senior pediatric oncology surgeon. All
operating decisions were discussed in a tumor board
meeting including a pediatric oncologist, a dedicated
pediatric radiologist, and a pediatric oncology surgeon.
Forty-eight patients included in our analysis were
enrolled in one of the 16 research-associated treatment
protocols (Table 2), which contain precise technical crite-
ria, indications, and instructions for tumor surgery. The
remaining two patients had renal sarcoma and adrenocor-
tical carcinoma, for which there are no such protocols.
These two patients were analyzed for postoperative com-
plications only.
Overall, compliance with such items was very high, with
997/1,053 items (95 %) meeting protocol requirements.
When analyzed by protocol, all patients enrolled in eight of
the 16 treatment protocols (50 %) had full (i.e. 100 %)
compliance with surgical requirements, and constituted
63 % of the overall procedures (n = 32/51).
Problematic items concerned mainly the documentation
of the required lymphatic node sampling in the operative
reports, more particularly the documentation of staging
(18/38 problematic items; 47 %). Such observation was
made when pathology reports, documenting lymph node
samples that were analyzed, were compared with the sur-
geon’s operative notes. This discrepancy did not affect
treatment decisions for any of the patients in our series.
There was no surgical mortality and no intensive care
unit admission, except for planned postoperative follow-up.
Twenty-one patients (43 %) had one or more complica-
tions, for a total of 34 complications (66 % of procedures).
Overall, 85 % of complications were grade 1 or 2
according to Clavien and Dindo.11 The most frequent
complication was postoperative fever, with ten occur-
rences. Documented infections occurred in two cases: one
central line infection with Staphylococcus epidermidis and
one urinary tract infection with Escherichia coli. In one
further case of clinical infection, S. epidermidis was found
on the gastrostomy but was not considered relevant. There
were no cases of sepsis. The other complications were
single occurrences. Out of eight patients who received a
TABLE 1 Clinical and demographic data of the study population
Total
[n (%)]
Included
[n (%)]
Survival
[n (%)]
Event-
free
survival
[n (%)]
No. of patients 61 (100) 50 (100) 42 (84) 39 (78)
M:F ratio 0.8 0.9 – –
Median age at
presentation
1 year
10 months
2 years
3 months
– –
Neuroblastoma 30 (50) 22 (44) 16 (72) 14 (63)
Nephroblastoma
(Wilms tumor)
12 (18) 12 (24) 12
(100)
11 (91)
Ganglioneuroma 6 (10) 4 (8) 4 4
PNET/Ewing 5 (9) 4 (8) 4 4
Ganglioneuroblastoma 2 (3) 2 (4) 2 2
Rhabdomyosarcoma 2 (3) 2 (4) 1 1
Renal clear cell
carcinoma
1 (2) 1 (2) 1 1
Renal fibroadenoma 1 (2) 1 (2) 1 1
Adrenocortical
carcinoma
1 (2) 1 (2) 1 1
Renal sarcoma 1 (2) 1 (2) 0 0
M male, F female, PNET primary neuroectodermic tumor
TABLE 2 Compliance with surgical protocols
Protocols No. of
patients
enrolled
No. of
procedures
Overall compliance to
surgical items in the
protocol (% of items
satisfactorily addressed)
Neuroblastoma
group
28 30
Protocol HR/ESIOP 4 6 90
Protocol LNESG2 8 8 92
Protocol INES 5 5 93
Protocol SIOP E.N. 2 2 95
Protocol 3961 2 2 93
Protocol POG 9640 2 2 100
Protocol 9641 1 1 85
Protocol NB87 2 2 100
Protocol NB90 2 2 100
Nephroblastoma
group
14 15
Protocol POG 9440 4 4 90
Protocol SIOP 2001 10 11 99
PNET 4 4
Protocol Euro-
Ewing 99
2 2 100
Protocol
AEWSOO31
1 1 100
Protocol POG 9457 1 1 100
Rhabdomyosarcoma 2 2
Protocol RMS 2005 1 1 100
Protocol
ARSTO331
1 1 100
Overall 48 51 96
PNET primary neuroectodermic tumor
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blood transfusion in the perioperative period, only one did
so because of massive surgical hemorrhage. All the other
blood transfusions were motivated by preoperative che-
motherapy-induced anemia.
Macroscopic gross total surgical excision was complete
in 40/48 patients (83 %). Incomplete macroscopic resec-
tion (n = 7) was found in stage III or IV neuroblastoma
(n = 5) and ganglioneuroma encasing the aorta or iliac
vessels (n = 2).
One patient experienced 180 days of pseudo-intestinal
obstruction after intestinal ischemia during Wilms tumor
resection and concomitant vincristine chemotherapy.
Postoperative pleural effusion required chest tube insertion
in two cases. Table 3 summarizes the complications
encountered and their grades according to Clavien and
Dindo.11 Table 4 details the complications.
Median time to enteral feeding was 1 day (mean
11 days). Median time to postoperative chemotherapy was
15 days (mean 16.2).
Outcomes for each type of tumor are summarized in
Table 1 and are detailed as follows:
There were 30 identified cases of neuroblastoma;
twenty-two required primary tumor resection and were
included in the study. Surgery was the sole treatment for
five patients with localized disease; all survived. The other
17 patients were included in infant or high-risk protocols.
Fifteen of these patients had stage III or IV requiring
neoadjuvant chemotherapy. Nine survived, giving a sur-
vival for stage III and IV tumors estimated at
approximately 60 %, and 53 % for stage IV alone. Four
died within 2 years of diagnosis, one within 5 years and
one after 5 years, all with stage IV disease without local
recurrence.
Among non-included patients, five survived without
surgery, two died of tumor progression under chemother-
apy, and one patient died of late metastatic disease. These
three patients were not candidates for surgery.
All patients with ganglioneuroma, ganglioneuroblas-
toma, PNET, Wilms tumor, renal clear cell carcinoma,
renal fibroadenoma, or adrenocortical carcinoma survived.
One patient with Wilms tumor needed a second operation
for a local recurrence. The patient with renal sarcoma died
6 years after diagnosis of metastatic disease without local
recurrence.
One patient with pelvic rhabdomyosarcoma needed
brachytherapy for local control and is still alive more than
3 years after diagnosis. The other patient with RMS of the
abdominal wall died of metastatic disease within 6 months
of diagnosis.
DISCUSSION
The aim of the study was to analyze retrospectively the
enrollment into standard-of-care treatment protocols, and
measure the rate of adverse events observed in our patient
population. We were able to observe that over 13 years of
pediatric solid tumor surgeries in a pSSCC in Switzerland,
all patients were included into international treatment
protocols. Compliance with the itemized sections of sur-
gical requirements in these protocols was very high (96 %),
and the rate of gross-total resections was 85 %. Complete
macroscopic excision was not always the ultimate goal of
surgery. For e.g. when efforts for complete removal could
TABLE 3 Details, grades, and rates of complications according to
Clavien and Dindo
N Rate (%)
No. of patients 48
No. of procedures 51
No. of complications 34 66 (of patients)
Grade 1 19 56 (of complications)
Grade 2 10 29
Grade 3a 0 0
Grade 3b 3 9
Grade 4a 2 6
Grade 4b 0 0
Grade 5 0 0
TABLE 4 Details of complications
Type of complication No. of cases Percentage of
cases
Fever (C38.5 C) 10 21
Documented infection 4 8
Intestinal necrosis 1 2
Infection/wound breakdown 1 2
Subileus 5 10
Need for oxygen supplementation 1 2
Abdominal compartment
syndrome
1 2
Cardiac arrhythmia 1 2
Pleural effusion 1 2
Pneumothorax 1 2
Subcutaneous emphysema 1 2
Chronic renal failure grade 1 1 2
Acute tubular necrosis 1 2
Hematuria 1 2
Lower limb edema 1 2
Ulnar nerve compression 1 2
Phrenic nerve injury 1 2
Hyponatremia 1 2
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jeopardize the patient’s safety with no known benefit in
survival. We noted the absence of any fatal outcome
directly linked to a surgical cancer-directed procedure.
Surgery did not delay further treatment as our patients were
ready for chemotherapy, when required, within an average
of 15 days from surgery. Overall, our data seems to suggest
that even with the modest caseload of a pSSCC within a
Swiss tertiary academic hospital, compliance with inter-
national standards can reach a high level. This is an
important finding, especially as it is known how difficult it
can be to implement recommendations consistently.12
Interestingly, while risk-stratification was not the pur-
pose of our study, we found our case-mix not to favor
lower complexity cases. In fact, as neural crest-derived
tumors are the most frequent thoracic and abdominal
tumors in children, they represented the larger fraction of
cases in this study (n = 28). Only eight cases (28 %) were
treated according to the LNSG2 protocol (localized L1,
using the new image-defined risk factor classification), as
indicated in Table 2; the other 20 cases (72 %) were more
complex cases. In comparison, in a recent Children’s
Oncology Group review,13 the low-risk group comprised
50 % of cases.
Survival for local neuroblastoma can be estimated at
100 %. Survival for stage III and IV was 60 and 53 % for
metastatic cases. Surgery was complete for 8/15 patients
with stage III and IV neuroblastomas. Incomplete resection
was made in accordance with the protocol in the remaining
7/15 patients. Only one of these seven patients required two
further surgical interventions for recurrences at the limit of
the irradiation field. Irradiation of the primary tumor site is
mandatory in all high-risk neuroblastoma protocols.
All but one of the patients with Wilms tumor survived
event-free after 4 years of follow-up, regardless of the
stage of the tumor (stage I, n = 4; stage II, n 4; stage III,
n = 2; stage IV, n = 1; and stage V, n = 1)
Despite the small figures that hamper any tentative
generalization, we feel that our case-mix and survival data
compare fairly to data recently published by larger
centers.14,15
We believe our findings reflect the existence of a com-
pulsory and regular multidisciplinary tumor-board
discussion in our center, leading to consensual and peer-
and openly-discussed treatment strategies, as well as con-
tinuous postgraduate surgical education. In fact, it has been
recognized in the literature that such procedural steps are
very important, as defective planning can lead to increased
morbidity and mortality in cancer patients.16
Our analysis has several limitations. Its retrospective
nature and the limited number of cases render any analysis
difficult to interpret. Regarding our adverse event analysis,
we deliberately chose to use a stringent definition of sur-
gical complications, as defined by Clavien and Dindo,11
which has the advantage of including all deviations from
the ideal postoperative course. As expected, using this
classification, our complication rate was accordingly high
with 34 patients out of 48 (66 %). Fortunately, severe
complications were rare, with 85 % being Clavien grade 1
or 2, requiring no or simple medical treatment. Surgical
management of complications was needed for chest tube
insertion in two cases. The single most frequent compli-
cation was postoperative fever without clinical infection,
which is not surprising in oncology patients. The rate of ten
occurrences in 51 procedures (19.6 %) found in our series
is actually very low compared with reported figures of up
to 79 % in another retrospective pediatric study.17
Our data also highlight several important improvement
opportunities. Pre-existing frailness is but one explanation
for the adverse events observed, but certainly does not
account for the occurrence of pneumothorax or ulnar nerve
compression. Although of no consequence to the patients,
lymphatic node sampling documentation in the operative
report was clearly below our expectations. This will require
an adaptation of our practice, through the compulsory use
of a protocol-specific intra-operative checklist and disease-
specific standardized surgical reporting forms clearly
prompting description of the nodal dissection status. The
impact for the patients of this specific weak point in our
documentation was limited, as the staging could be ade-
quately retrieved from the histological examination reports
in retrospect. This data reveals that surgery was properly
performed even if the surgical report was imperfect. In
2005, the National Wilms Tumor Study Group reported
9 % of the required lymph node sampling not being per-
formed,18 which may have a significant impact on tumor
staging and hence therapy.
Conceptually, there are several advantages of care
within a pSSCC, to which our positive data could hint. At
baseline, a recent study in the field of pediatric brain tumors
showed no evidence that the quality of care differed between
smaller and larger centers.19 In addition, one might argue that
the size of our unit might facilitate the rapid, smooth, and
effective implementation and updating of surgical recom-
mendations, and therefore directly positively impact quality
of care. In addition, the small human resource turnover, and
close-up surgical education of younger colleagues, could
contribute to overall improved services to our patient pop-
ulation. The disadvantages certainly include the limited
numbers of cases, which negatively influences the time
required to build a solid pool of experience for such complex
and highly specialized procedures. In such settings, recruit-
ment and training of younger surgeons and their long-term
mentoring is paramount. All of the above considerations
have a clearly speculative nature, but well-designed studies
by smaller-scale pediatric surgical oncology units could be
performed to answer them.
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The small throughput in institutions such as ours makes
it hard to reach statistical significance in outcome studies
outside international protocols, and this was not the aim of
our work. However the adherence to these protocols can be
quite easily monitored as one quality indicator, along with
the rate of undesired events. We feel that our study could
serve as an example to foster open and objective data-
sharing between pSSCCs, and enhance critical self-review
and quality of care measurements to ultimately benefit our
patient populations.
CONCLUSION
In our 14-year retrospective study assessing adherence
to treatment protocols and surgical adverse events as
quality indicators in abdominal and thoracic pediatric solid
tumor surgery we identified a high rate of adhesion to
surgical protocols, few serious complications, and no sur-
gical mortality. Our data suggests that meticulous surgical
planning and execution by dedicated oncologic pediatric
surgeons, and tight collaboration with pediatric oncolo-
gists, are absolute prerequisites for quality in our care.
Under these conditions, even pSSCC can meet the stan-
dards set by larger, leading centers.
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